This grant from the National Institute of Mental Health is for advancing translational research aimed at better understanding the emergence and worsening of mood and psychotic disorders, such as perimenopausal depression, generalized anxiety, bipolar disorder, and schizophrenia, during the menopause transition. The primary purpose is to identify novel targets for future treatment interventions. This funding opportunity encourages innovative, interdisciplinary studies exploring the underlying neurobiological and behavioral mechanisms of these conditions. Areas of interest include the interplay of classic depressive symptoms with menopause symptoms like hot flashes and sleep disturbances, the influence of reproductive steroids, accurate diagnosis at different menopausal stages, co-occurring psychiatric and menopause symptoms, and the impact of psychosocial factors in midlife.
Opportunity ID: 335877
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-22-036 |
| Funding Opportunity Title: | Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.242 — Mental Health Research Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Sep 21, 2021 |
| Last Updated Date: | Jan 13, 2023 |
| Original Closing Date for Applications: | Jan 07, 2025 |
| Current Closing Date for Applications: | Jan 13, 2023 |
| Archive Date: | Feb 12, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | County governments Native American tribal governments (Federally recognized) City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities State governments Small businesses Private institutions of higher education Special district governments Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-22-036.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| expired and re-issued as PAR-23-102 | Jan 13, 2023 | |
| Sep 21, 2021 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-22-036 |
| Funding Opportunity Title: | Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.242 — Mental Health Research Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Sep 21, 2021 |
| Last Updated Date: | Jan 13, 2023 |
| Original Closing Date for Applications: | Jan 07, 2025 |
| Current Closing Date for Applications: | Jan 13, 2023 |
| Archive Date: | Feb 12, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | County governments Native American tribal governments (Federally recognized) City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities State governments Small businesses Private institutions of higher education Special district governments Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-22-036.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-22-036 |
| Funding Opportunity Title: | Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.242 — Mental Health Research Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 21, 2021 |
| Last Updated Date: | Sep 21, 2021 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jan 07, 2025 |
| Archive Date: | Feb 12, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education City or township governments Native American tribal governments (Federally recognized) Private institutions of higher education Small businesses Special district governments For profit organizations other than small businesses Public housing authorities/Indian housing authorities State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-22-036.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Related Documents
Folder 335877 Full Announcement-PAR-22-036 -> PAR-22-036-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00270329 | Jan 16, 2022 | Jan 14, 2023 | View | |
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00269072 | Jan 16, 2022 | Jan 24, 2022 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00278141 | Nov 08, 2022 | Jan 14, 2023 | View |
Package 1
Mandatory forms
335877 RR_SF424_5_0-5.0.pdf
335877 PHS398_CoverPageSupplement_5_0-5.0.pdf
335877 RR_OtherProjectInfo_1_4-1.4.pdf
335877 PerformanceSite_4_0-4.0.pdf
335877 RR_KeyPersonExpanded_4_0-4.0.pdf
335877 PHS398_ResearchPlan_4_0-4.0.pdf
335877 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
335877 RR_Budget_3_0-3.0.pdf
335877 RR_SubawardBudget30_3_0-3.0.pdf
335877 PHS398_ModularBudget_1_2-1.2.pdf
335877 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
335877 RR_SF424_2_0-2.0.pdf
335877 PHS398_CoverPageSupplement_5_0-5.0.pdf
335877 RR_OtherProjectInfo_1_4-1.4.pdf
335877 PerformanceSite_2_0-2.0.pdf
335877 RR_KeyPersonExpanded_2_0-2.0.pdf
335877 PHS398_ResearchPlan_4_0-4.0.pdf
335877 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
335877 RR_Budget_1_4-1.4.pdf
335877 RR_SubawardBudget30_1_4-1.4.pdf
335877 PHS398_ModularBudget_1_2-1.2.pdf
335877 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
335877 RR_SF424_5_0-5.0.pdf
335877 PHS398_CoverPageSupplement_5_0-5.0.pdf
335877 RR_OtherProjectInfo_1_4-1.4.pdf
335877 PerformanceSite_4_0-4.0.pdf
335877 RR_KeyPersonExpanded_4_0-4.0.pdf
335877 PHS398_ResearchPlan_5_0-5.0.pdf
335877 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
335877 RR_Budget_3_0-3.0.pdf
335877 RR_SubawardBudget30_3_0-3.0.pdf
335877 PHS398_ModularBudget_1_2-1.2.pdf
335877 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
